Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of PM8002 in Combination With Etoposide and Platinum in First-line Treatment of Extensive-Stage Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase II Clinical Trial to Evaluate the Efficacy and Safety of PM8002 in Combination With Etoposide and Platinum in First-line Treatment of Extensive-Stage Small Cell Lung Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etoposide (Primary) ; PM-8002 (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Biotheus

Most Recent Events

  • 05 May 2025 According to the BioNTech media release, preliminary data from this study presented at the European Lung Cancer Congress (ELCC), March, 2025.
  • 12 Mar 2025 Protocol was amended, to change phase II/III to phase II, and phase III will be integrated to another global III study (NCT06712355). Arms changed from 2 to 1 ; active comparator arms (Atezolizumab+Etoposide+platinum) has been removed.
  • 12 Mar 2025 According to ClinicalTrials.gov: US National Institutes of Health, In the first part of the study, 50 participants were enrolled as of 21 Nov 2023 and recruitment was completed. The second part is randomized, double-blind study, active controlled design , which will be integrated to another global III study (NCT06712355).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top